冠心病的防治策略：疾病重在预防、技术重在规范、药物治疗是基础，再血管化治疗(PCI &CABG)是利刃。合理整合的策略应具有个体化，Evidence-based，Value-based。
基于12个网页-相关网页
靶病变再血管化治疗 target lesion revascularization ; TLR
动脉再血管化治疗研究 Arterial Revascularisation Therapy Study
靶血管再血管化治疗 target vessel revascularization ; TVR
As a intraluminal operation, revascularization will unavoidably damage the endothelium and maybe cause the restenosis (RS) which is the major complication of angioplasty. Even in the era of stenting, the occurrence rate of restenosis is still as high as 12%-23%.
这样，作为血管腔内的操作，再血管化治疗不可避免的要损伤血管内皮，这有可能导致术后再狭窄(restenosis RS)，是血管成形术后期主要的并发症，严重影响再血管化治疗的效果，即使在支架时代，其发生率仍高达12％-32％。
参考来源 - 骨髓间充质干细胞移植和干细胞动员对血管损伤修复及功能影响的对比研究·2,447,543篇论文数据，部分数据来源于NoteExpress
当前杂交再血管化治疗复杂冠脉疾病治疗的长期获益证据有哪些？
What is the evidence of long term benefit of hybrid revascularization for complex coronary artery disease?
这些资料提示在NSTEMI患者的早期再血管化的临床研究中，延长随访时间对于验证治疗获益是必要的。
These data suggest that in clinical investigations of early revascularization among patients with NSTEMI, extended follow-up may be necessary to demonstrate treatment benefit.
治疗包括入路选择、闭塞段的开通和再血管化。
The method includes acess selecting, recanalization of occlusions and revascularization.
应用推荐